Media

Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke
Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Expert Investor Rates Algernon Pharmaceuticals as an Immediate Buy
Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough
Streetwise Reports – Hedge Fund Doubles Position in Biotech Co.
MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs
Research Capital Corporation – Additional Phase 2a Analysis by a Chronic Cough KOL
Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity
Research Capital Corporation – Breathing Easier – Liftoff! – IPF Phase 2a Data Hits
Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage
Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level?
Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251
Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022
Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study
Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study
This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion
Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA
Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes
Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4
Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud
Algernon Presents Psychiatrist and Author Rick Strassman, MD on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD
Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT
Powerplay by the Market Herald Interviews Christopher J. Moreau, CEO
DMT Increases Growth of Rat Neurons by 40 Percent, New Data Shows
Proactive Investors Interview – Algernon Pharmaceuticals files a pre-IND meeting request with US FDA for Ifenprodil Small Cell Lung Cancer Study
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 3
The Dales Report – Preclinical Study Shows Microdoses of DMT Increased Growth of Neurons
Upfront with Algernon Pharmaceuticals CEO Christopher J. Moreau – Episode 2
Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%
Psychedelic Finance – Interview with Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Interview with Dr. William North – Algernon Pharmaceuticals Lead Consultant for its Small Cell Lung Cancer Ifenprodil Research Program
Share via
Copy link
Powered by Social Snap